Cytokinetics (NASDAQ:CYTK) Given New $100.00 Price Target at Mizuho

Cytokinetics (NASDAQ:CYTK) had its price target hoisted by Mizuho from $84.00 to $100.00 in a research report released on Wednesday,Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently issued reports on CYTK. UBS Group lifted their target price on shares of Cytokinetics from $61.00 to $69.00 and gave the stock a “neutral” rating in a research note on Friday, March 6th. Bank of America reissued a “neutral” rating on shares of Cytokinetics in a research note on Wednesday, February 25th. The Goldman Sachs Group set a $95.00 price target on shares of Cytokinetics and gave the stock a “buy” rating in a research report on Thursday, December 18th. Jefferies Financial Group reaffirmed a “buy” rating and set a $90.00 price objective on shares of Cytokinetics in a research note on Friday, January 9th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Cytokinetics from $74.00 to $75.00 and gave the company an “overweight” rating in a report on Tuesday. Seventeen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Cytokinetics has a consensus rating of “Moderate Buy” and an average price target of $89.89.

Cytokinetics Price Performance

Shares of Cytokinetics stock opened at $62.19 on Wednesday. The stock has a market capitalization of $7.66 billion, a P/E ratio of -9.52 and a beta of 0.56. The business has a 50 day simple moving average of $63.80 and a two-hundred day simple moving average of $60.94. Cytokinetics has a 12 month low of $29.31 and a 12 month high of $70.98.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.02). The firm had revenue of $17.76 million during the quarter, compared to analysts’ expectations of $8.02 million. During the same quarter in the previous year, the company earned ($1.26) earnings per share. Cytokinetics’s revenue was up 4.9% on a year-over-year basis. As a group, research analysts anticipate that Cytokinetics will post -5.24 EPS for the current fiscal year.

Insider Buying and Selling at Cytokinetics

In related news, EVP Fady Ibraham Malik sold 12,033 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $62.15, for a total transaction of $747,850.95. Following the completion of the sale, the executive vice president directly owned 153,902 shares in the company, valued at approximately $9,565,009.30. This trade represents a 7.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Sung Lee sold 4,935 shares of Cytokinetics stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $62.15, for a total transaction of $306,710.25. Following the transaction, the executive vice president directly owned 87,127 shares in the company, valued at $5,414,943.05. This trade represents a 5.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 159,663 shares of company stock worth $9,944,292. Corporate insiders own 2.70% of the company’s stock.

Institutional Trading of Cytokinetics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in Cytokinetics by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 12,048,131 shares of the biopharmaceutical company’s stock valued at $765,538,000 after acquiring an additional 191,336 shares during the last quarter. State Street Corp increased its stake in Cytokinetics by 3.7% during the fourth quarter. State Street Corp now owns 5,825,295 shares of the biopharmaceutical company’s stock worth $370,139,000 after acquiring an additional 207,961 shares during the last quarter. Deep Track Capital LP raised its position in Cytokinetics by 17.8% in the third quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company’s stock valued at $236,328,000 after purchasing an additional 650,000 shares during the period. Geode Capital Management LLC raised its position in Cytokinetics by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 3,056,017 shares of the biopharmaceutical company’s stock valued at $194,214,000 after purchasing an additional 15,815 shares during the period. Finally, Vestal Point Capital LP lifted its stake in shares of Cytokinetics by 14.8% in the 2nd quarter. Vestal Point Capital LP now owns 2,975,000 shares of the biopharmaceutical company’s stock valued at $98,294,000 after purchasing an additional 384,469 shares during the last quarter.

Key Headlines Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Mizuho raised its price target on CYTK from $84 to $100 and kept an “outperform” rating — a large upside that supports further buying interest. Mizuho raise
• Positive Sentiment: JPMorgan raised its price target slightly (from $74 to $75) and maintained an “overweight” rating, reinforcing institutional confidence. JPMorgan note
• Positive Sentiment: Barclays reiterated its Buy rating on Cytokinetics, adding to the cluster of bullish analyst views that support momentum. Barclays article
• Neutral Sentiment: Cytokinetics granted inducement awards (options for 8,628 shares and 5,719 RSUs) to five new hires under Nasdaq Rule 5635(c)(4) — standard recruiting compensation that is dilutive over time but not an operational red flag. Inducement grants
• Neutral Sentiment: Analytical coverage assessing CYTK valuation after new MYQORZO trial data and safety outcomes is circulating — useful for longer‑term thesis but not a single near‑term catalyst. Valuation analysis
• Negative Sentiment: CEO Robert I. Blum sold 36,601 shares on March 17 at an average ~$62.15 (~$2.27M), reducing his stake by ~7.8% — a large insider sale that may be read as executive profit‑taking. CEO Form 4
• Negative Sentiment: EVP Fady Ibraham Malik sold 12,033 shares on March 17 at ~$62.15 (~$747.9k), a ~7.25% cut to his holdings. Malik Form 4
• Negative Sentiment: EVP Andrew Callos executed several recent sales (including 8,542 shares on Mar 17 at ~$62.15 and 1,930 shares on Mar 18 at ~$62.07), further reducing insider holdings — consistent with ongoing, sizable executive selling. Callos Form 4
• Negative Sentiment: EVP Sung Lee sold 4,935 shares on Mar 17 at ~$62.15 (~$306.7k), trimming his stake by ~5.4%. Multiple senior‑level sales together may temper investor enthusiasm despite analyst optimism. Lee Form 4

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.